Anti-IgE: A treatment option in allergic rhinitis?

被引：11

作者：

Pfaar, O. ^{[1
]}

Gehrt, F. ^{[1
]}

Li, H. ^{[1
]}

Rudhart, S. A. ^{[1
]}

Nastev, A. ^{[1
]}

Stuck, B. A. ^{[1
]}

Hoch, S. ^{[1
]}

机构：

[1] Philipps Univ Marburg, Sekt Rhinol & Allergol, Klin Hals Nasen & Ohrenheilkunde, Univ Klinikum Giessen & Marburg GmbH,Standort Mar, Marburg, Germany

来源：

ALLERGOLOGIE | 2021年 / 44卷 / 03期

关键词：

omalizumab; biologics; allergic rhinitis; anti-IgE; FC-EPSILON-RI; ANTIIMMUNOGLOBULIN-E THERAPY; MONOCLONAL-ANTIBODY; COMPLEX-FORMATION; DOWN-REGULATION; HUMAN BASOPHILS; OMALIZUMAB; ASTHMA; SAFETY; PHARMACODYNAMICS;

D O I：

10.5414/ALX02205E

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Background: Allergic rhinitis (AR) is the most common IgE-mediated allergic disease. Multiple clinical trials have demonstrated promising results on the AR treatment with biologics, in particular with the use of omalizumab - an anti-IgE antibody. Omalizumab has also been established in the routine management of allergic asthma und chronic idiopathic urticaria. However, currently there is no approved license for the use of biologics in AR in Germany. Methods: A systematic literature review has been completed including randomized controlled trials, meta-analyses, and reviews on the treatment of AR with omalizumab. Results: The systematic review demonstrates strong evidence supporting the use of omalizumab in the treatment of AR with regards to symptom control, safety profile, and management of comoibidities. Conclusion: Omalizutnab is a good and safe option in the treatment of AR in terms of symptom control and the management of pre-existing comoibidities. Further clinical trials with other biologics in the management of AR are needed and are expected to follow soon.

引用

页码：199 / 209

页数：11

共 50 条

[1] Anti-IgE treatment in allergic rhinitis
Muluk, Nuray Bayar
Bafaqeeh, Sameer Ali
Cingi, Cemal
[J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2019, 127
[2] Omalizumab - An effective anti-IgE treatment for allergic asthma and rhinitis
Casale, TB
[J]. DRUGS OF TODAY, 2004, 40 (04) : 367 - 376
[3] Anti-IgE for the treatment of allergic rhinitis - and eventually nasal polyps?
Verbruggen, K.
Van Cawenberge, P.
Bachert, C.
[J]. ALLERGOLOGIE, 2007, 30 (09) : 338 - 353
[4] Anti-IgE for the Treatment of Allergic Rhinitis and Eventually Nasal Polyps?
Verbruggen, Katia
Van Cauwenberge, Paul
Bachert, Claus
[J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2009, 148 (02) : 87 - 98
[5] Anti-IgE in allergic asthma and rhinitis: an update
Morjaria, Jaymin B.
Gnanakumaran, Gnanasekaran
Babu, Kesavan Suresh
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (11) : 1739 - 1747
[6] Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis
Chervinsky, P
Casale, T
Townley, R
Tripathy, I
Hedgecock, S
Fowler-Taylor, A
Shen, H
Fox, H
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 91 (02) : 160 - 167
[7] The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis
Kopp, MV
Brauburger, J
Riedinger, F
Beischer, D
Ihorst, G
Kamin, W
Zielen, S
Bez, C
Friedrichs, F
von Berg, A
Gerhold, K
Hamelmann, E
Hultsch, T
Kuehr, J
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 110 (05) : 728 - 735
[8] The use of anti-IgE in the treatment of allergic asthma
Bush, RK
[J]. MEDICAL CLINICS OF NORTH AMERICA, 2002, 86 (05) : 1113 - +
[9] Can anti-IgE treatment be treatment option in nonallergic severe asthmatic patients? Can anti-IgE be an alternative treatment for severe non-allergic asthma?
Kutlu, Ali
Demirer, Ersin
Ozturk, Sami
Kartal, Ozgur
[J]. TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2013, 61 (02): : 162 - 163
[10] Anti-IgE in the treatment of allergic disorders in pediatrics
Fried, Ari J.
Oettgen, Hans C.
[J]. CURRENT OPINION IN PEDIATRICS, 2010, 22 (06) : 758 - 764

← 1 2 3 4 5 →